Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma ; volume:14 ; number:1 ; day:11 ; month:7 ; year:2014 ; pages:1-11 ; date:12.2014
BMC cancer ; 14, Heft 1 (11.7.2014), 1-11, 12.2014

Creator: Oliver, Jaime Antonio

Contributor: Ortiz, Raúl
Melguizo, Consolación
Álvarez, Pablo Juan
Gómez-Millán, Jaime
Prados, Jose
SpringerLink (Online service)

DOI: 10.1186/1471-2407-14-511

URN: urn:nbn:de:1111-2016030419612

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Oliver, Jaime Antonio
Ortiz, Raúl
Melguizo, Consolación
Álvarez, Pablo Juan
Gómez-Millán, Jaime
Prados, Jose
SpringerLink (Online service)

Other Objects (12)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

Related objects

Reset password